M RI, WITH ITS excellent depiction of soft tissues and multiple contrast mechanisms, has become a hallmark for imaging of musculoskeletal disease. However, as assessment of multiple tissue types and functional processes is necessary for optimized detection and diagnosis of musculoskeletal diseases, as well as for studying disease pathogenesis and treatment response, one imaging modality may not be ideal. To address this concern, multimodality imaging systems have been introduced into clinical radiology to combine the strengths and overcome the limitations of various individual imaging modalities. In particular, hybrid positron emission tomography (PET) and MRI (PET-MRI) systems are an emerging technology that aim to combine the highresolution soft-tissue information from MRI with simultaneous functional and molecular information from PET and may have numerous indications for clinical and research studies of musculoskeletal disease. 1, 2 While the first commercial hybrid PET-MRI system were only recently installed in 2010, their numbers have been increasing steadily. There have been several exemplary reviews of both the technical aspects of simultaneous PET-MRI [3] [4] [5] [6] [7] [8] [9] as well as their clinical application in oncology soft tissues injuries such as intervertebral disc injuries; tears in the menisci, ligaments and tendons; and occult bone injuries. 13 In evaluation of musculoskeletal tumors, MRI has been traditionally used to identify the extent of disease for treatment planning, but new MRI methods such as diffusion-weighted imaging (DWI), chemical shift MRI, perfusion imaging, and MR spectroscopy (MRS) have shown the potential to screen, diagnose and characterize musculoskeletal neoplasms. 14 Additionally, advanced quantitative MRI techniques that can provide unique cellular information are used to study pathogenesis in many musculoskeletal disorders. [15] [16] [17] While MRI is unmatched in its ability to evaluate soft tissue and bone marrow pathology, it has some limitation for imaging osseous abnormalities. Specifically, the lower water content and rapid signal decay of bone, particularly cortical bone, make quantitative MRI difficult. New methods such zero echo time (ZTE) MRI and ultra-short echo time (uTE) have shown promise for visualization of cortical bone 18 and for assessment of fracture risk. 19 Nevertheless, functional imaging of bone with MRI remains a challenge. PET offers incomparable ability to provide quantitative information about molecular and metabolic activity that often precedes structural and even biochemical changes. Many different PET radiotracers have been applied to imaging musculoskeletal applications (Table 1 ). In particular, two commercially available PET tracers are commonly used to study musculoskeletal disease. Fluorine-18 ( cose, is the most widely used PET radiotracer in clinical practice and is able to relay information about tissues with increased metabolic activity and glucose consumption. 20 FDG is extensively used in oncology for tumor staging, detection of metastasis and tumor recurrence, and for monitoring response to therapy. FDG PET is also a useful tool to identify musculoskeletal inflammation and infection due to increased glucose usage by activated inflammatory cells. 21 Additionally, 18 F-sodium fluoride ( 18 F-NaF) is a longrecognized PET bone-seeking agent. 22 , 23 18 F-fluoride ion is able to exchange with the hydroxyl groups in hydroxyapatite crystals on the surface of bone matrix to form fluoroapatite. 24 Thus, uptake of 18 F-NaF is concentrated preferentially at sites of newly mineralizing bone and provides a marker of bone metabolism. 25 18 F-NaF is used in the detection and evaluation of skeletal metastasis, particularly in tumors with low FDG affinity such as thyroid and renal cell cancers. 23, 26 Furthermore, 18 F-NaF provides an excellent opportunity to study bone turnover and repair in nononcologic musculoskeletal disorders such as metabolic bone diseases, arthritic diseases, and fracture healing. 23, 27 While PET imaging is unmatched for molecular imaging, it needs the assistance of higher-resolution, anatomic information to localize these physiologic processes. It is most often combined with CT imaging, which is able to provide not only high resolution anatomic detail but also attenuation correction information for acquired PET data. 28 While PET/CT has become essential for evaluation of oncologic disease, its utility as a stand-alone modality for characterization of musculoskeletal disease (including cancers) has been limited, largely due to the unparalleled soft tissue contrast of MRI.
New integrated PET-MRI systems potentially provide a complete imaging modality for musculoskeletal imaging, combining simultaneous molecular and physiologic information from PET with the high spatial resolution and soft tissue contrast information of MRI to provide a superior level 
Applications of PET-MRI in Oncologic Musculoskeletal Disease
Bone and Soft Tissue Sarcomas Bone sarcomas (BS) and soft tissue sarcomas (STS) represent a rare and heterogeneous group of mesenchymalderived malignancies, accounting for approximately 1% of adult cancers. Imaging plays a pivotal role in the diagnosis, staging, and restaging of these tumors. Therapy is typically multimodal and includes surgery, radiation therapy, and both cytotoxic and targeted chemotherapy. Staging BS and STS relies upon a multi-faceted approach. MRI is the gold standard modality for assessing T-stage given its excellent soft tissue contrast, high spatial resolution, and multiplanar capability. It is critical in preoperative and radiation planning, depicting tumor relationship to neurovascular structures, fascial planes, muscular compartments, and adjacent joints. [29] [30] [31] Of interest, a retrospective study examining the diagnostic accuracy of FDG PET/ CT and conventional imaging (including MRI) of a heterogeneous cohort of 117 BS and STS showed slightly better T-staging by FDG PET/CT (overall accuracy 96%) compared with conventional imaging (94% accuracy). 32 
FDG
PET has also been shown to help identify tumor-free surgical margins before surgical resection. 33 Therefore, combined PET-MRI may confer some advantage in T-staging compared with standalone MRI. The addition of novel MRI techniques such as DWI with apparent diffusion coefficient (ADC) mapping, dynamic contrast enhancement (DCE), and MRS may improve diagnostic accuracy compared with conventional MRI. 30, 34, 35 Combining these with metabolic measures such as standardized uptake values (SUV), total lesion glycoslysis (TLG), and metabolic tumor volume (MTV) provides powerful multiparametric evaluation. Indeed, the combination of metabolic and spectroscopic evaluation on FDG PET-MRI has been explored in STS, 36 and a radiomics model combining texture features from FDG PET-MRI has been used to identify factors most predictive of lung cancer metastases in 51 patients with extremity STS. 37 Additional benefits of adding localized PET evaluation to MRI for primary BS and STS assessment include prognostication and guiding biopsy. Baseline BS and STS FDG activity has been shown to independently predict survival in several studies. [38] [39] [40] [41] [42] More recently, two larger meta-analyses have confirmed the prognostic value provided by baseline PET/CT in BS and STS. 43 Dedicated PET evaluation of the primary lesion may also allow sampling of the most FDG avid and highest-grade areas of tumor. 44 This can be especially critical in large and high-grade sarcomas, which may exhibit extensive necrosis and heterogeneity, and thus be prone to nondiagnostic biopsy or undersampling (Fig. 1) . Although BS and STS sarcomas most commonly metastasize to the lungs, 45 retroperitoneal and visceral sarcomas may hematogenously spread to the liver, myxoid liposarcomas have a propensity for bone (especially spine) and soft tissue metastases, and several STS including synovial sarcoma and rhabdomyosarcoma have a predilection for nodal metastases. 46 The metabolic information afforded by FDG PET/CT has been shown to confer superior sensitivity to conventional imaging (CI) techniques for detecting nodal metastases (N-stage), in both BS and STS. 47, 48 It has also proven superior in detecting distant metastases (Mstage), 47, 48 and shown to upstage both Ewings's sarcoma and osteosarcoma patients relative to CI. 49 However, highresolution chest CT has higher sensitivity for detecting pulmonary metastases, 50,51 particularly those less than 1 cm, 48 and, therefore, diagnostic chest CT will remain an essential component of sarcoma staging and follow-up. A recent study examined the role of FDG PET-MRI in staging of 29 BS and STS patients. T and M stage was identical for PET-MR and CI in all patients. One patient with a thoracic wall rhabdomyosarcoma was found to have N1 disease on PET-MRI versus N0 on CI, but this did not alter therapy. In the remaining 28 patients, PET-MRI and CI yielded identical N stage. ROC analysis for distant metastasis detection showed a sensitivity of 97.8% and specificity of 100% for PET-MRI, compared with 94.4% and 100% for CI, but this was not statistically significant (P 5 0.51). Several additional case series and pilot studies have also shown benefit of PET-MRI in evaluating STS. [52] [53] [54] There are clear advantages to combined PET and MRI for therapy response assessment and disease monitoring. The utility of FDG PET for response assessment after chemotherapy has been demonstrated for both STS 55 and BS, 56 and quantitative ADC analysis has been used to assess response on MRI. 34, 35 While it seems intuitive that combining PET and MRI would be additive or perhaps synergistic in determining treatment response, early studies have shown discordant results between PET and MRI measures, 57, 58 and further study is needed to examine the role of integrated PET-MRI in assessing therapy response. Evaluation of local recurrence on MRI in the posttreatment setting may be hindered by signal abnormality and enhancement within the operative bed, and FDG PET can show inflammatory uptake in the same regions.
Integrated PET-MRI has been recently shown to have benefit compared with MRI alone for the identification of locally recurrent soft tissue sarcomas. In a study of 41 patients with clinically suspected sarcoma recurrence, the sensitivity, specificity, and diagnostic accuracy for detecting local recurrence was 82%, 86%, and 83% for MRI, versus 96%, 79%, and 90% for PET-MRI, respectively (P > 0.05). Furthermore, PET-MRI showed higher confidence levels (P < 0.05) for delineating malignant lesions. 59 Earlier studies have shown FDG PET to have similar sensitivity and increased specificity compared with conventional imaging in recurrent osteosarcoma and Ewing's sarcoma, 60 and equal accuracy in assessing locally recurrent and distant metastatic disease in pediatric sarcoma patients. 61 Future prospective studies are expected to define the role of integrated PET-MRI in the posttherapy setting. In conclusion, FDG PET-MRI for BS and STS is useful for providing prognostic information, guiding biopsy, and staging disease during initial evaluation, helpful in identifying local recurrence, and holds promise for assessing treatment response.
Multiple Myeloma
Multiple myeloma (MM) is a hematologic malignancy of plasma cells characterized by bone marrow infiltration and immunoglobulin overproduction. In the revised 2014 International Myeloma Working Group (IMWG) criteria, diagnosis requires evidence of clonal marrow plasma cells 10% or biopsy-proven plasmacytoma and one or more myeloma-defining events, which include CRAB features (hypercalcemia, renal insufficiency, anemia, one or more osteolytic bone lesions > 5 mm) or specific biomarkers including clonal bone marrow plasma cells 60%, serum free light chain ratio 100, or more than one marrow replacing lesion > 5 mm on MRI. 62 Therefore, imaging plays a key role in diagnosing active MM, although it is not strictly needed for the diagnosis. Cross-sectional imaging is preferred for detection of bone lesions in patients with suspected myeloma, and one of three modalities can be used depending on availability, cost, and/or institutional preference: whole body low dose CT, whole-body MRI (WBMRI), or FDG PET/CT. The most recent IMWG consensus guidelines endorse MRI as the gold standard for imaging the axial skeleton, evaluating painful lesions, and for distinguishing benign from malignant compression fractures. It is recommended for the work-up of solitary bone plasmacytoma, and the IMWG recommends whole-body MRI, or spine and pelvic MRI at minimum, in all patients with smoldering or asymptomatic myeloma. 63 18 F-FDG PET/CT should be used to confirm a diagnosis of solitary plasmacytoma if whole-body MRI is unavailable, and to differentiate between smoldering and active myeloma, if whole-body x-ray is negative and WBMRI is unavailable. FDG PET/CT is also the preferred functional imaging modality to evaluate and monitor therapy. 64 There is no current consensus statement on the use of FDG PET-MRI in myeloma patients from the IMWG, but it has been incorporated into the diagnostic algorithm at several institutions. 65 MRI has been proven to be more sensitive in depicting MM lesions than radiographs, except for rib lesions. 66 /s has been shown to be 100% sensitive and 98% specific for diagnosing a diffuse marrow pattern. 75 MRI also confers prognosis; the presence of more than one focal lesion on MRI is an independent predictor of progression to symptomatic disease and development of osteolytic bone lesions. 76, 77 The diffuse pattern of involvement has been correlated with worse prognosis, greater burden of disease, and high-risk cytogenetics. 78, 79 MRI's ability to demonstrate focal and diffuse disease and the quantitative potential of ADC hold promise for monitoring treatment response. Positive response on conventional MRI sequences includes decrease in size and/or number of focal lesions, normalization of a diffuse pattern, and in focal lesions, the appearance of a peripheral halo of T 1 hyperintense fatty marrow, or complete fatty replacement, also called fatty metamorphosis. It has been also been shown that mean ADC increased in 95% of MM responders and a 3.3% ADC increase resulted in 90% sensitivity and 100% specificity in detecting positive treatment response, 80 which has been supported by other studies. 74 Like MRI, FDG PET/CT is more sensitive than radiographs, 67, 68, 70 and performs equally well to MRI in detecting focal lesions, but is inferior for detecting diffuse disease. [67] [68] [69] [70] [71] Some studies have shown correlation between SUVmax on PET/CT and bone marrow cellularity and plasma cell ratios on bone marrow biopsy sample. 81 PET/ CT also has excellent ability for detecting extramedullary disease (EMD), 82 which is important given that approximately 10% of MM patients will develop EMD during the course of their disease. 83 The prognostic value of FDG PET/CT is better established than MRI. The presence of three or more lesions is an independent predictor of overall survival (OS), 84 while a SUVmax of greater than 4.2 and presence EMD adversely affect progression free (PFS) and OS. 85 A positive PET/CT has also been associated with quicker progression of smoldering myeloma to active myeloma. 86 Interestingly, some studies have shown higher probability of progression if focal FDG avid lesions also exhibit osteolysis, 87 while others have not shown osteolysis on PET/CT to be predictive. 86 Despite this, the updated IMWG guidelines necessitate the presence of osteolysis to make the diagnosis of active disease on PET/CT. 62 The benefit of FDG PET/CT in assessing treatment response was well-demonstrated in a recent metaanalysis combining 10 studies involving 690 myeloma patients. 88 PET/CT may demonstrate disease response earlier than MRI, as resolution of FDG activity is typically seen before MRI signal normalization. 89, 90 A negative PET/CT after therapy is an independent predictor for prolonged PFS and OS in patients with complete response. 91 The literature detailing PET-MRI performance in multiple myeloma is limited. A study comparing WBMRI and PET/CT in assessment of active disease in MM found better sensitivity and specificity for MRI, but noted that when used in combination, PET and WBMRI were found to have a specificity and positive predictive value of 100%, heralding a role for integrated PET-MRI. 92 Another study showed equivalency of PET/CT and PET-MRI for detection of myeloma lesions in 30 patients; finding 94% of focal lesions identified on the PET portion of PET/CT were also seen on the PET portion of PET-MRI. PET-MRI missed rib lesions that were seen on PET/CT evaluation, not surprising given that WBMRI has documented limitations in evaluation of skull, ribs, and clavicles. 66 In conclusion, PET-MRI in multiple myeloma shows vast potential given the high accuracy of both PET/CT and MRI to detect focal lesions, MRI's advantage in diffuse disease, prognostic information afforded by both, and PET's well-evidenced ability to determine response to therapy. In our personal experience, PET-MRI has been helpful in cases of diffuse disease, better depicted on MRI than PET (Fig. 2) , and also in showing resolution of FDG activity in responding lesions before resolution of signal abnormality on MRI (Fig. 3 ).
Bone Metastases
The skeleton is one of the most frequent sites of metastatic disease, most commonly from breast and prostate cancer.
presence of osseous metastases. 93 A few studies examining the role of FDG PET-MRI in bone metastasis have been performed. A study comparing FDG PET-MRI and PET/CT in 67 oncology patients with a spectrum of primary malignancies found higher detection of osseous metastases for PET-MRI (100%) versus PET/CT (94%), especially in small lesions. 97 Lesion conspicuity was high for both modalities, but greater on PET-MRI (P < 0.05). However, this may have been in part because of greater uptake time on PET-MRI (152 min) versus PET/CT (60 min). A separate study examined sequential FDG PET/ CT and PET-MRI in 24 oncology patients and found similar overall detection rates but higher reader confidence with PET-MRI versus PET/CT. 98 In a study of 109 patients with breast cancer undergoing same-day contrast enhanced FDG PET/CT and PET-MRI, PET-MRI demonstrated superior sensitivity (96% versus 85%), and was positive in 12% of patients deemed negative for osseous metastasis on PET/ CT. 99 A retrospective study comparing 68 Ga-PSMA PET-MRI and PET/CT in prostate cancer showed 100% concordance between PET-MRI and PET/CT in evaluating bone metastases, but overall higher conspicuity of bone lesions on MRI compared with CT (P < 0.006). 100 In conclusion,
PET-MRI has excellent diagnostic performance in evaluating osseous metastases, and there is growing evidence of an advantage compared with PET/CT given increased lesion conspicuity and reader confidence with PET-MRI.
Applications of PET-MRI in Nononcologic Musculoskeletal Disease
Osteoarthritis Osteoarthritis (OA) is a leading cause of pain and disability, and is characterized by degeneration of joint tissues. 101 There is tremendous effort toward understanding OA and development of drugs to address both the causes and symptoms of disease. These endeavors are often undermined by a lack of noninvasive tools to detect early and reversible disease changes. Furthermore, there is increasing evidence that OA is a disease of the whole joint with numerous phenotypes, suggesting that reliable biomarkers are necessary for better understanding, prevention, diagnosis, and treatment of OA. MRI provides an excellent opportunity to noninvasively study the complex disease processes involved in OA. 102 In addition to its excellent high-resolution and multi-contrast morphologic information of joint tissues, advanced quantitative MRI techniques may provide important information about tissue microstructure such as collagen matrix organization, glycosaminoglycan (GAG) content, and hydration, which is thought to degrade before structural changes are seen with conventional imaging methods. 103, 104 PET imaging with 18 F-NaF provides a method to assess subchondral bone activity in OA. Functional imaging of subchondral bone is vital, as this is the only highly vascularized tissue in the joint and has the ability to reflect rapid changes. Furthermore, increased bone remodeling has been implicated as a mechanism of OA progression that affects not only bone but also adjacent tissues. 105, 106 The gold standard for assessment of bone remodeling with bone biopsy is costly, invasive, and spatially limited. Measurement of biochemical markers of bone resorption and formation in the serum or urine is limited to global changes. Bone activity measured with 18 F-NaF has been shown to correlate with bone histomorphometry. 25 Early studies in OA patients showed uptake of 18 F-NaF was significantly increased in hip joints which had bone abnormalities on separately performed MRI. 107 Furthermore, the uptake of 18 F-NaF in the patellofemoral compartment of the knee has been shown to correlate with the presence of patellofemoral pain. F-NaF PET-MRI has shown promise for comprehensive whole-joint imaging. A feasibility study in patients with knee pain or prior knee injury showed that the 18 F-NaF PET uptake in subchondral bone marrow lesions (BML), osteophytes, and sclerosis identified on MRI was significantly higher than that of normal appearing bone on MRI (Fig. 4a) . Furthermore, a correlation was observed between BML and osteophyte grades based on the MRI Osteoarthritis Knee Score (MOAKS) and SUV max in those lesions. Of interest, more than half of small, grade 1 osteophytes identified on MRI, often described as the earliest morphologic sign of OA, did not correlate with high 18 FNaF uptake (Fig. 4b) . 109 This observation suggests that 18 FNaF PET provides a quantitative measure to characterize degenerative lesions and understand which play a more important role in the progression of OA. Importantly, 37% (63/172) of high uptake regions on 18 F-NaF PET had no correlative abnormality on MRI (Fig. 4c) . Furthermore, in patients with unilateral, reconstructed anterior cruciate ligament (ACL) tears within 10 years of their injury, who have a known increased risk for developing accelerated OA, significantly increased 18 F-NaF PET uptake was observed in the subchondral bone of ACL-reconstructed knee joints, compared with their uninjured contralateral knees. 110 As molecular changes often precede changes at the tissue level, these findings suggest increased bone activity detected with 18 F-NaF PET may serve as a marker for early OA in this population.
Another benefit of hybrid PET-MR imaging of OA is that it uniquely allows the simultaneous evaluation of not only early mechanisms of disease, but also spatial relationships between them and across tissues. Current whole-joint assessments of OA with MRI largely rely on semiquantitative scoring systems, which subjectively evaluate tissue structures. 111 In a study of mild to moderate OA patients, increases in cartilage T 1q relaxation times, which are associated with a loss of cartilage GAG content, were correlated with increased bone as well as reduced uptake in the nonadjoining compartments. 112 In a separate study of patients with unilateral, reconstructed ACL tears, a correlation was observed between increased 18 F-NaF uptake measures of bone remodeling and increased T 2 values in adjacent cartilage, which is indicative of early collagen matrix breakdown. 110 This correlation was particularly pronounced in the deep layers of cartilage adjacent to the subchondral bone. This supports an interdependent relationship between bone and cartilage with early degenerative changes in one tissue having an effect on the neighboring tissue. In addition to 18 F-NaF, FDG has been used to study the role of inflammatory processes in OA pathogenesis. In particular, FDG has been applied to study synovitis and the inflammatory component of BMLs in OA. A diffuse increase in FDG uptake was seen in OA patients compared with healthy age-matched controls, which the authors attributed to the presence of synovitis in OA. 113, 114 While contrast-enhanced MRI is often used to detect synovitis, FDG offers a tool for early detection and quantitative characterization of inflammation in the synovial membrane. BMLs, which are identified as regions of increased bone marrow signal on fat-suppressed T 2 -weighted fast spin-echo MRI images, are associated with OA pain and disease progression, but their etiology is difficult to evaluate. Together, PET and MRI offer a unique combination to identify BMLs and characterize their molecular composition. Preliminary PET-MRI evaluation of BMLs in patients with prior knee injury or knee pain showed that BMLs identified on MRI had high 18 F-NaF uptake and negligible increased FDG uptake relative to normal-appearing bone 109 ( Fig. 5 ).
This suggests that BMLs in OA are not primarily driven by inflammatory processes. However, further studies are necessary to validate these findings and evaluate the longitudinal progression of molecular processes in these lesions. In summary, PET-MRI offers a new paradigm for imaging of OA pathogenisis; offering simultaneous acquisition of multiple markers of early disease process across all joint tissues. This can provide new insights into OA pathogenesis and help objectively evaluate the efficacy of new disease modifying therapies.
Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a painful inflammatory autoimmune disease characterized by systemic inflammation, and destruction of articular and periarticular tissues. Conventional radiography has long been used to detect structural changes, including osseous erosions and joint space narrowing. However, new targeted disease modifying antirheumatic drugs (DMARDs) have revolutionized treatment of RA by aiming for sustained remission of disease. This has shifted strategies for management of RA from symptom relief to early institution of disease-modifying therapy to prevent structural damage and disability. 115 Patient outcomes are thus tied to the timing of expensive but powerful therapy. As a result, new imaging methods capable of detection and treatment monitoring of early inflammatory and cellular changes in RA offer the ability to change clinical management of these patients. MRI is a powerful tool for detection and treatment of RA. MRI can detect soft tissue and bone marrow affected by inflammation before development of structural lesions seen on radiography or CT. Furthermore, contrast enhancement with intravenous gadolinium can effectively detect synovitis, bursitis, tenosynovitis, osteitis, and bone erosions and differentiate active inflammation. MRI has shown efficacy for disease confirmation when conventional methods were inconclusive, which is vital to optimize initiation of DMARD treatment and maximize long-term outcomes. 116 MRI can also provide prognostic information. In particular, BMLs detected with MRI are strongly correlated with future radiographic findings of RA and progression on MRI. 117 For patients undergoing RA therapy and those in remission, MRI scoring systems that evaluate RA features show great potential for monitoring disease, particularly for risk stratification when considering options for tapering biologic therapy. 118 FDG PET is able to quantitatively image elevated glucose usage in cells mounting an immune response and thus offers a quantitative and more sensitive method for evaluation of the joint inflammation and synovitis that are the hallmarks of RA. FDG uptake has been correlated with disease activity and C-reactive protein levels in RA patients. 119 Furthermore, it has been used to evaluate the extent of whole-body involvement in RA, 120 clinical outcomes, and treatment efficacy in early RA patients undergoing DMARD therapy. 12 In addition to FDG PET, additional PET tracers may offer new molecular targets with greater sensitivity to inflammation. For example, 11 C-choline can target cellular proliferation 122 while 11 C-(R)-PK11195 targets proteins on activated macrophages and may offer a more specific molecular marker of inflammation.
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PET-MRI can boost the application of molecular imaging techniques to study RA and improve the clinical utility of imaging in all aspects of disease. PET may provide the most sensitive method for detection and quantitative characterization of inflammation in RA, while MRI provides an optimal technique for musculoskeletal imaging and evaluation of morphologic changes. The feasibility of simultaneous PET-MRI for imaging inflammation has been demonstrated in early RA of the hand, showing sites of synovitis and tenosynovitis on contrast-enhanced MRI that corresponded to increased uptake on FDG PET (Fig. 6) . 124 This multi-modality approach can potentially change the clinical approach for evaluation of RA; using imaging markers of inflammation as a treatment target and for clinical evaluation of disease remission.
Imaging of Pain Generators
Neuropathic pain is a debilitating pain symptom secondary to neural damage in the somatosensory nervous system. 125 It often accompanies significantly amplified pain responses to mildly painful stimuli, nonpainful stimuli, or no stimuli at all. Approximately 10% of the general population in the United States, corresponding to 15.7% of total pain patients, was estimated to have some form of neuropathic pain in a recent survey. 126 For locating the causative nerve damage of neuropathic pain, electromyography and nerve conduction studies are most widely used. Unfortunately, these tests entail painful, invasive needle electrode placement, and the test outcome is strongly subject to the practitioner's skills. 127 MRI has increasingly gained attention as an alternative diagnostic method to noninvasively identify a variety of nerve damage. 128 However, the detected structural nerve abnormalities are often very subtle or can be even irrelevant to the pain symptom. 129 Therefore, there is a pressing need for noninvasive diagnosis with improved sensitivity and specificity to identify sources of neuropathic pain.
FDG PET-MRI has shown promising results in diagnosis for neuropathic pain. The main assumption of this approach is that the neuroinflammatory process in the painful nerve lesion may result in hypermetabolic activity, presenting as focally high FDG uptake in the PET image. Here, co-registration of the PET image with high-resolution MRI facilitates identification and localization of increased FDG uptake within nerve tissues. An animal study validated this assumption with a rat-model experiment by demonstrating significantly increased FDG uptake at the site of spared-nerve injury compared with the contralateral side and controls. 130 The feasibility of FDG PET-MRI for human study was recently demonstrated with chronic sciatica patients. Sciatica is one of the most common neuropathic pain sources, characterized by radiating pain from the lower back to lower extremities along the sciatic nerve. Spinal nerve impingement by a herniated disc is the most likely cause of sciatica, but it is a structural abnormality with a very high false-positive rate, frequently observed in asymptomatic subjects as well. 129 FDG PET-MRI has shown utility to detect neuroinflammation along impinged spinal nerves (Fig. 7) . Joint analysis using FDG uptake and morphologic MRI features demonstrated potential for detecting nonspinal sources of sciatica and ruling out nerve root impingements irrelevant to the patient's symptoms. A careful analysis is required to correlate increased FDG uptake with neuropathic pain sources, because there can be many non-pain-related factors that cause elevated FDG uptake. A more specific radioligand, 18 F-FTC- specifically binds to sigma-1 receptors, a transmembrane protein that becomes increasingly expressed in the nervous system with many neurological diseases that cause neuropathic pain. 132, 133 An in vivo animal study showed the increased uptake of 18F-FTC-146 at the site of nerve injury, 132 demonstrating its feasibility as a neuropathic pain marker. The biodistribution and radiation dosimetry of 18F-FTC-146 in human controls were presented to validate its safety and stability for PET-MRI on human subjects. 134 The recent application of 18F-FTC-146 PET-MRI to patients with complex regional pain syndrome showed that the imaging findings altered the pain management plan for 7 of 8 patients, and change of therapy in two patients achieved a considerably improved pain-relief outcome. 135 In conclusion, PET-MRI for neuropathic pain has demonstrated promising results in detection of causative nerve damage, which has altered pain management and achieved better patient outcomes. Novel pain-specific PET tracers can further improve identification of pain generators, allowing PET-MRI imaging to serve as a valuable diagnostic method for challenging neuropathic pain cases when conventional diagnostic methods have been exhausted.
Osteoporosis and Metabolic Bone Diseases
Metabolic bone diseases, such as osteoporosis, osteomalacia, and Paget's disease affect bone strength and result in fractures and bone deformities if left untreated. Clinical assessment in these diseases is aimed at evaluation of bone structure and bone mass to understand the risk of future fractures. Digital X-ray radiogrammetry (DXR) and dual energy X-ray absorptiometry (DEXA) are the most common clinical imaging tests to evaluate bone mass in these subjects, but do not provide information regarding bone architecture, quality, and turnover which are critical features for understanding bone strength. Measurement of regional bone metabolism with 18 FNaF PET is appealing to study the metabolic imbalance in bone formation and resorption that may underlie metabolic bone disorders. 18 F-NaF PET uptake in women has been shown to positively correlate with age in the humeral shaft and negatively correlate with age in the lumbar spine, with significant differences in uptake in both regions observed between pre-and postmenopausal women. 136 18 F-NaF PET has also been applied to evaluating therapeutic efficacy in osteoporosis. Kinetic modeling of 18 F-NaF PET upake in 18
women with osteoporosis showed an increase in bone mineralization after 6 months of treatment with teriparatide, an anabolic agent that increases bone density and reduces the risk of fragility fractures. 137 The increase in uptake varied regionally, with the largest response to treatment seen in the femoral shaft and the smallest observed in the spine. The authors interpreted these finding as teriparatide having a greater effect in formation of cortical bone than trabecular bone, given the greater proportion of cortical bone in the femur and trabecular bone in the spine. These findings are in conflict with previous studies of bone densitometry, and highlight the potential for PET to evaluate regional changes of bone turnover and provide biomarkers in metabolic bone disease.
CT is appealing for studying metabolic bone disorders due to its high-resolution contrast of bone architecture and ability to provide quantitative information about bone mineral density. However, MRI may offer a more optimal modality for studying fracture risk and high-resolution morphologic imaging to pair with nuclear medicine techniques. While direct imaging of bone is challenging with MRI, the trabecular microstructure and volume can be accurately measured from signal void in high-signal-intensity fatty bone marrow. 15 Additionally, MRI can better visualize bone marrow and can differentiate between red and yellow marrow. Recent work that applied 18 F-NaF PET and MRI sequentially to image the femoral neck showed that FDG uptake was dependent on the composition of bone marrow. 138 This is particularly interesting as yellow bone marrow contains mesenchymal stem cells that can differentiate into osteoblasts and directly affect bone metabolism. In addition to morphology and bone marrow composition, MRI can quantitatively evaluate cortical bone water content as a surrogate of bone porosity. 139 uTE MRI measures of cortical bone water have been correlated to measures of bone quality and strength in bone specimens and has been used to show that cortical bone pore water increases in populations with increased fracture risk. 140 In summary, PET- MRI provides complementary information which can improve quantitative assessment of bone strength and prediction of fracture risk in characterization of disease and evaluation of therapeutic efficacy.
Osteomyelitis and Spondylodiscitis
Simultaneous PET-MRI may also provide superior diagnostic capabilities in suspected osteomyelitis and spondylodiscitis. Accurate and timely diagnosis of these infections is critical as antibiotic therapy can be curative and prevent bone or spinal deformity, neurologic deficits or amputation. 141 As the typical clinical presentation of osteomyelitis and spondylodiscitis is usually heterogeneous and nonspecific, imaging often plays a crucial role in diagnosis and characterization of disease. Similar to the previously discussed applications, the superior contrast in bone marrow, vertebra, intervertebral discs, and neural structures have made MRI the current imaging method of choice to confirm suspected bone or spinal infection. However, presence of edema on MRI, usually seen as high signal on T 2 -weighted sequences or after injection of intravenous contrast, may lack specificity in osteomyelitis.
FDG PET can be used to differentiate between active inflammation and degenerative changes seen on MRI, thereby improving specificity. In a retrospective study of patients who underwent both MRI and FDG PET for a suspected diagnosis of osteomyelitis, a simulated imaging strategy showed that if PET or MRI was equivocal for osteomyelitis, the addition of the other modality resulted in the correct diagnosis. 142 Furthermore, recent work showed that simultaneous FDG PET-MRI significantly increased diagnostic certainty for detection of spondylodiscitis in patients with inconclusive clinical or MRI findings (Fig. 8) . 143 In that prospective study of 30 patients, simultaneous 18 F-FDG PET-MRI improved the sensitivity from 54% to 100% and the specificity from 71% to 88% compared with MRI alone. MRI included pre-and postcontrast standard MRI spine sequences and histopathology or clinical follow-up were used as a reference standard. In this study, neither the C-reactive protein level nor the leukocyte count showed any relationship to the reference standard diagnosis of spondylodiskitis. In conclusion, PET-MRI in osteomyelitis and spondylodiscitis shows promise for improved diagnostic certainty to allow for earlier initiation of treatment and improved clinical outcomes in these patients. 
Other Nononcologic Musculoskeletal Applications
PET-MRI has been applied to study muscle activation. 144 FDG PET, which measures glucose uptake and is thus sensitive to muscle metabolism and activity, was used as a reference standard to study the relationship between T 2 relaxation time changes and glucose uptake in skeletal muscle after exercise. Simultaneous acquisition of PET and MRI data allowed for analysis of the two quantitative measures following the same exercise paradigm on the same time course, which would not have been possible with sequential scanning. Thus, integrated PET-MRI systems are necessary for dynamic imaging of acute changes in physiology with both modalities. Furthermore, PET-MRI presents an excellent opportunity to use the superior molecular sensitivity of PET to validate functional MRI methods that may offer higher resolution and applicability without ionizing radiation.
PET-MRI has also been applied to the diagnosis of stress fractures. Stress fractures are common overuse injuries in athletes that result from abnormal increased stress on normal bone. Radiographs have poor sensitivity to stress fractures and positive findings may take several weeks to months to appear. MRI can detect bone marrow edema well in advance of changes on radiographs and differentiate fractures from soft tissue injuries, thus becoming an important imaging modality for stress fractures. PET imaging with 18 F-NaF can detect increased bone turnover at the site of new bone formation around a stress fracture within a few days after onset of symptoms and thus offers optimal sensitivity to detect the earliest signs of stress fractures. PET-MRI was shown to be useful for diagnosis of stress fractures and stress reactions in cases where no pathological findings were present on X-ray (Fig. 9) . 145 A separate study in patients with foot pain of unclear cause showed that in cases of stress fracture, PET-MRI performed better than PET/CT due to earlier depiction of T 1 -weighted MRI changes than changes on CT, which provided higher diagnostic confidence. 146 Overall, the authors saw that 18 F-NaF PET-MRI provided more diagnostic information and higher diagnostic confidence compared with PET/CT for evaluation of foot pain of unclear cause. This was largely attributed to diagnostically relevant findings from soft-tissue and bone marrow pathology on MRI. The authors also showed a high correlation between SUV measurements on PET-MRI and PET/CT, demonstrating that PET-MRI is technically feasible and robust.
Technical Considerations and Challenges
Technical advancements in solid state photodetectors that are MRI-compatible have made integrated PET-MRI systems possible. 5, 147 There are several commercially available PET-MRI scanners including sequential and now more common, integrated designs. All of these systems use 3 Tesla static magnetic field strengths for MRI. Current technical considerations and challenges in PET-MRI revolve around correction of attenuation of PET photons using MR images, PET-MRI workflow, and quantification and interpretation of data. 3, 5, 7, 9 The specifics of these technical considerations in musculoskeletal imaging are discussed below.
MR-Based Attenuation Correction
During reconstruction, PET data needs to be corrected to account for attenuation of photons as they pass through tissue and hardware to accurately quantify PET uptake. Unlike CT, where Hounsfield units can directly be converted to linear attenuation at the PET 511 keV energy level, MRI signal is a function of tissue proton density and relaxation properties and does not relay any direct information about attenuation correction (AC) for PET data. Instead, current F-NaF PET-MRI fusion (d) of the ankle of a 58-year-old female patient. X-ray images were negative, while CT show sclerotic lesions in the dorsal calcaneus (red arrow) and degenerative changes in the talonavicular region but no signs of acute stress fractures. On MRI, a fracture line in the dorsal calcaneus with little edema is seen, due to an older stress fracture that corresponds to elevated 18 F-NaF PET uptake (red arrow). Additionally, another stress fracture is shown on PET-MRI in the mediodorsal parts of the cuboid with bone marrow edema on MRI and elevated uptake on 18 F-NaF PET (dotted arrow). 145 Reprinted from commercial MR-based attenuation correction (MRAC) methods primarily use a segmentation-based approach where Dixon fat-water separated images are used to identify softtissues and fat, which are then assigned known AC coefficients. However, this still leaves challenges to correct for MRI hardware, bone, and metal implants that affect musculoskeletal imaging but do not have signal on conventional MRI.
Bone
Bone has higher PET photon attenuation than soft tissues but is challenging to account for in MRAC due its short T 2 relaxation time that results in a lack of signal on conventional MRI. Attenuation correction for bone is particularly critical for PET-MRI of musculoskeletal disorders, which either involve direct imaging of bone or imaging of structures in close proximity to bone. Misclassifying bone in AC maps may result in underestimation of PET uptake in and around the osseous structures. 148 Atlas-based methods, which account for bone by registering MR images to an anatomic atlas, are commonly used to account for bone in the head but do not completely account for variations in patient bone structure and density. 8 Methods based on uTE or zTE MRI have shown promise to not only offer patientspecific bone morphology, but also to estimate continuousvalued attenuation coefficients for bone. 149 Furthermore, new methods have been developed using a deep learning based approach for generating pseudo CT attenuation correction maps from acquired ZTE and Dixon images. 150 Data are processed with a convolutional neural network that has been taught to learn spatial patterns and multiparametric correlations to generate a continuous-valued AC map. This method is able to capture variations in bone density, and provides substantial improvements in SUV accuracy near bony anatomy.
MRI Hardware
Attenuation correction (AC) for MRI coils is a new challenge for PET quantification that came with the introduction of hybrid PET-MRI systems. 151, 152 159, 160 For PET imaging, the metal-induced artifacts in the CT or MRI images used to derive the PET attenuation coefficient map results in errors in the reconstructed PET uptake maps (Fig. 10) . Additionally, for MRI, the large attenuation from the implant itself is ignored. A reconstruction approach jointly estimating the attenuation coefficient map and radioactivity showed promise for mitigating the tracer quantification errors in PET near metallic implants. 161 Adoption of metal-artifact-corrected MRI images was introduced to generate a more accurate attenuation coefficient map near metallic implants for the PET image reconstruction. 162, 163 Furthermore, phantom experiments demonstrated that classification of metal and soft tissues using MRI could be feasible, achieving significant correction for the underestimation of the PET tracer uptake. 164 
MRAC Conclusion
MRAC methods have progressed substantially in the past 5 years since the advent of integrated PET-MRI systems. While many of the advanced methods mentioned above are still not widely available or have been developed for a specific anatomy or pathology, there is an encouraging trend toward incorporation of these techniques in commercially available MRAC methods in the near future.
Workflow Considerations
Hybrid PET-MRI workflow needs to be tailored for each application to optimize data acquisition and is still a work in progress. Scan time is most often constrained by MRI acquisitions times. Oncologic studies or imaging of musculoskeletal pain often require five to eight bed positions for whole-body coverage. This largely limits MRI acquisition time to 3-5 min per PET bed. This will often include one to two anatomic sequences as well as a mandatory scan for MRAC. As the MRI field of view (FOV) in the superiorinferior position can be greater than that of PET bed, MRI sequences can be extended across multiple PET beds to increase the number of MRI contrasts collected. A longer MRI protocol can be used for comprehensive anatomical imaging or for supplemental functional scans such as DWI in specific anatomy of interest but scan time must always be balanced against patient comfort. In contrast, PET-MRI studies where the anatomy of interest is constrained to one PET bed, such as the knee or foot, permit longer MRI protocols. As the entire duration of MRI scan time can be used for PET data acquisition, this allows for a considerable reduction in the injected radiotracer dose. Furthermore, as MRI does not produce any ionizing radiation, PET-MRI can provide a drastic reduction in effective radiation dose to patients, which is vital for imaging of pediatric patients and for the widespread adoption of nuclear medicine techniques for nononcologic musculoskeletal imaging.
Quantification and Interpretation of PET Uptake
PET imaging is able to provide quantitative information regarding metabolic and molecular processes, but requires an understanding of the tracer uptake mechanisms for proper interpretation. PET uptake is most commonly quantified by using SUV, which measures the tissue activity concentration (in kBq/mL) normalized for the injected activity and the patient body weight. This method provides the simplest method to express uptake and has been shown to be reproducible and reliable. 165 However, SUV provides a semiquantitative measure of PET radiotracer uptake. As there is only a finite amount of tracer, SUV measurements are affected by the delivery and availability of the tracer at any particular site, and thus can be affected by several biologic and physical factors. 166 While SUV has been shown to be effective for detection and characterization of tumors, caution should be taken when comparing SUV between different patient cohorts or in longitudinal evaluation of musculoskeletal disease. Pharmacokinetic modeling of dynamic PET uptake offers a more quantitative approach to PET image analysis. 167 Kinetic modeling requires acquisition of PET listmode data, usually for 45 min or more, immediately after injection of the radiotracer. The PET data are then reconstructed into dynamic frames of varying temporal length, usually shorter frames immediately after injection and longer frames at the end. Lastly, dynamic PET activity is fit to a compartmental model to determine rate constants that describe the movement of PET radiotracer between blood, extracellular, and intracellular compartments (Fig. 11) . These rate parameters are absolute and can be compared between anatomical regions as well as patient populations. However, compared with static SUV measurements, kinetic modeling of dynamic PET uptake is more challenging, often limited to one PET bed, and requires a considerably longer PET acquisition time. Furthermore, models are dependent on an accurate arterial input function (AIF), a measure of tracer activity in arterial blood. 168 Nevertheless, in PET-MRI applications of musculoskeletal disease where one anatomic region is being evaluated and extended scan times are necessary for MRI evaluation, kinetic modeling can provide accurate quantification as well as additional metabolic information. Additionally, PET-MRI may provide an optimal method to calculate an accurate image-derived input function (IDIF). High resolution MR angiography can provide a true arterial volume, which in combination with dynamic PET data, can provide an accurate IDIF that is localized to the anatomy of interest without the time delay and invasiveness that may be present with arterial blood sampling. 169 
Conclusion
While widespread application of integrated PET-MRI in musculoskeletal disease is still limited, in part due to the more limited availability of the systems and challenges in workflow and reimbursement, these multimodality systems offer great promise. As MRI is often the imaging modality of choice in many musculoskeletal disorders, and new UTE and ZTE methods provide enhanced visualization of osseous anatomy, it is reasonable that PET-MRI may replace PET/ CT in many musculoskeletal exams. This is particularly true for applications where PET/CT and MRI are already performed sequentially as part of clinical care. Furthermore, the addition of molecular PET information to established MRI applications might offer earlier detection, improved sensitivity, and greater specificity in many nononcologic musculoskeletal diseases. In applications where only one anatomic region is of interest, PET-MRI can be performed with minimal increase in scan time and substantially reduced PET radiotracer dose. While several technical and workflow considerations require further innovation and improvement for accurate and optimized PET-MRI, there is an encouraging trend in recent scientific developments to resolve these limitations. The remaining challenge for adoption of PET-MRI into routine clinical practice will be demonstration of sufficient benefit to justify the cost and added complexity of these systems.
